{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:41:45Z","timestamp":1785548505551,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s15010-026-02734-w","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:15:05Z","timestamp":1775132105000},"page":"1265-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trial"],"prefix":"10.1007","volume":"54","author":[{"given":"Jingtao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiru","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katleen","family":"Callewaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Lounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyasha","family":"Bakare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2734_CR1","unstructured":"Global tuberculosis report 2024.Geneva: World Health Organization; 2024 [cited 2025 Apr 27]; Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024."},{"issue":"1","key":"2734_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2471\/BLT.13.122028","volume":"92","author":"G Brigden","year":"2014","unstructured":"Brigden G, Nyang\u2019wa BT, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68\u201374. https:\/\/doi.org\/10.2471\/BLT.13.122028.","journal-title":"Bull World Health Organ"},{"issue":"8","key":"2734_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300","volume":"9","author":"SD Ahuja","year":"2012","unstructured":"Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. https:\/\/doi.org\/10.1371\/journal.pmed.1001300.","journal-title":"PLoS Med"},{"issue":"5707","key":"2734_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223\u20137. https:\/\/doi.org\/10.1126\/science.1106753.","journal-title":"Science"},{"key":"2734_CR5","unstructured":"The use of bedaquiline in the treatment of multidrug resistant tuberculosis: interim policy guidance.Geneva: World Health Organization; 2013. [cited 2025 16 June]; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/84879\/9789241505482_eng.pdf."},{"key":"2734_CR6","unstructured":"World Health Organization consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. [cited 2025 Apr 27]; Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/332397\/9789240007048-eng.pdf?sequence=1."},{"key":"2734_CR7","unstructured":"World Health Organization treatment guideline for drug-resistant tuberculosis (2016 update). 2016 [cited 2025 Apr 27]; Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549639."},{"key":"2734_CR8","unstructured":"World Health Organization consolidated guidelines on drug resistant tuberculosis treatment. 2019 [cited 2025 Apr 27]; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311389\/9789241550529-eng.pdf?ua=1."},{"issue":"10366","key":"2734_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02307-8","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022;400(10366):1858\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(22)02307-8.","journal-title":"Lancet"},{"key":"2734_CR10","unstructured":"World Health Organization consolidated guidelnes on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. 2022 [cited 2025 Apr 28]; Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/365308\/9789240063129-eng.pdf?sequence=1."},{"issue":"1","key":"2734_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05870-w","volume":"21","author":"T Weng","year":"2021","unstructured":"Weng T, Sun F, Li Y, et al. Refining mdr-tb treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis. 2021;21(1):183. https:\/\/doi.org\/10.1186\/s12879-021-05870-w.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2734_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-07946-9","volume":"25","author":"J Gao","year":"2024","unstructured":"Gao J, Gao M, Du J, et al. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. Trials. 2024;25(1):227. https:\/\/doi.org\/10.1186\/s13063-024-07946-9.","journal-title":"Trials"},{"issue":"1","key":"2734_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-024-03694-4","volume":"22","author":"Y Song","year":"2024","unstructured":"Song Y, Shu W, Pei Y, et al. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin\/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China. BMC Med. 2024;22(1):401. https:\/\/doi.org\/10.1186\/s12916-024-03694-4.","journal-title":"BMC Med"},{"issue":"1","key":"2734_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10986-4","volume":"25","author":"R Akpata","year":"2025","unstructured":"Akpata R, Ntakpe JB, Messou E, et al. Tuberculosis disease characteristics associated with mortality, severe morbidity and unsuccessful treatment in people living with HIV treated for tuberculosis - a secondary analysis of the ANRS 12300 Reflate TB2 trial. BMC Infect Dis. 2025;25(1):695. https:\/\/doi.org\/10.1186\/s12879-025-10986-4.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2734_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-016-0214-0","volume":"21","author":"Q Huang","year":"2016","unstructured":"Huang Q, Yin Y, Kuai S, et al. The value of initial cavitation to predict re-treatment with pulmonary tuberculosis. Eur J Med Res. 2016;21(1):20. https:\/\/doi.org\/10.1186\/s40001-016-0214-0.","journal-title":"Eur J Med Res"},{"issue":"5","key":"2734_CR16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3201\/eid2505.181823","volume":"25","author":"L Mbuagbaw","year":"2019","unstructured":"Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2019;25(5):936\u201343. https:\/\/doi.org\/10.3201\/eid2505.181823.","journal-title":"Emerg Infect Dis"},{"issue":"25","key":"2734_CR17","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang'wa","year":"2022","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, et al. A 24-Week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2117166.","journal-title":"N Engl J Med"},{"issue":"9","key":"2734_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2119430.","journal-title":"N Engl J Med"},{"issue":"5","key":"2734_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa2400327","volume":"392","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti L, Khan U, Vel\u00e1squez GE, et al. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. N Engl J Med. 2025;392(5):468\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2400327.","journal-title":"N Engl J Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02734-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:46:11Z","timestamp":1782920771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02734-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2734"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02734-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}